Chronic Obstructive Pulmonary Disease Market Expected to Grow at a CAGR of 6.3% Through 2034, DelveInsight Analysis Reveals

The Chronic Obstructive Pulmonary Disease (COPD) market was valued at approximately USD 11.5 billion in 7MM (2024) and is projected to experience strong growth at a CAGR of 6.3% during the forecast period through 2034. DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the COPD landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The COPD market is increasingly guided by biomarker-driven strategies and the introduction of biologic therapies. The recent approval of DUPIXENT (dupilumab) marked the beginning of the biologic era in COPD, signaling a shift from bronchodilator-based management to targeted, biomarker-driven care. The subsequent approval of NUCALA (mepolizumab) in May 2025 expanded the biologics landscape as the first IL-5 inhibitor for COPD, validated in a broad eosinophilic population.

COPD is currently the third most common cause of global morbidity and mortality. COPD is primarily present in smokers, especially in the age group greater than 40 years. The prevalence increases with age; however, the prevalence is likely underestimated owing to underdiagnosis of COPD. Age plays a significant role in COPD prevalence, with individuals aged 65 and older being more affected than those under 65.

DelveInsight's report, "Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast-2034," provides a comprehensive analysis of the COPD landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines the Chronic Obstructive Pulmonary Disease market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Chronic Obstructive Pulmonary Disease market outlook, drug uptake, treatment scenario and epidemiology trends, visit the COPD Market Report

Some of the Key Facts of the Chronic Obstructive Pulmonary Disease Market Report:

• Key COPD Companies: GSK, AstraZeneca, Sanofi, Regeneron, Genentech/Roche, Takeda, Boehringer Ingelheim, Pfizer, Novartis, Mitsubishi Tanabe Pharma, Zambon, Chiesi, Sunovion, Mundipharma, Mylan, Teva, Sandoz, and others
• Key COPD Therapies: DUPIXENT (dupilumab), NUCALA (mepolizumab), FASENRA (benralizumab), Trelegy Ellipta (fluticasone/umeclidinium/vilanterol), Advair (fluticasone/salmeterol), LAMA/LABA combinations, Triple therapies, Ohtuvayre (ensifentrine), EMP-012, Lunsekimig, Itepekimab, and others
• The COPD market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage COPD pipeline products will significantly revolutionize COPD market dynamics.

Chronic Obstructive Pulmonary Disease Overview

Chronic Obstructive Pulmonary Disease (COPD) is a serious chronic lung disease presenting with persistent respiratory symptoms and airflow limitation that grows and spreads through progressive deterioration of lung function. COPD includes subtypes such as chronic bronchitis and emphysema, and may be driven by environmental exposures, smoking history, and genetic predisposition. Risk factors include smoking, environmental exposures including air pollution, and genetic predisposition. Early detection through spirometry and personalized treatment approaches improve patient outcomes and reduce disease burden.

Key Trends in Chronic Obstructive Pulmonary Disease Therapeutics Market:

• Biologic Therapy Expansion: The introduction of monoclonal antibodies targeting specific inflammatory pathways, including IL-5 inhibitors (NUCALA, FASENRA) and IL-4Rα antagonists (DUPIXENT), marking a paradigm shift from traditional bronchodilator management to targeted biologic-driven care
• Precision Medicine & Biomarker Testing: Enhanced molecular diagnostics and eosinophil count-based patient stratification enabling personalized treatment strategies and biomarker-driven patient selection
• New Small Molecule Therapies: Development of novel dual-acting bronchodilators and small-molecule therapeutics, such as ensifentrine (Ohtuvayre), offering alternative mechanisms of action for improved patient outcomes
• Combination Therapy Strategies: Rising adoption of triple-therapy inhalers and multi-agent combinations optimizing lung function and reducing exacerbation rates
• Digital Health Integration: Use of smart inhalers, remote monitoring technologies, and telemedicine to enhance medication adherence, optimize treatment, and improve patient outcomes

Chronic Obstructive Pulmonary Disease Epidemiology

The report provides a comprehensive analysis of the Chronic Obstructive Pulmonary Disease prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on key disease subtypes, including chronic bronchitis and emphysema. The report also highlights risk factors, disease burden, and projections for future trends, helping stakeholders understand the scope of COPD and plan targeted interventions, research, and treatment strategies.

Chronic Obstructive Pulmonary Disease Epidemiology Segmentation:

The Chronic Obstructive Pulmonary Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of COPD in the 7MM
• Subtype-specific Diagnosed Prevalent Cases of COPD in the 7MM
• Gender-specific Diagnosed Prevalent Cases of COPD in the 7MM
• Age-specific Diagnosed Prevalent Cases of COPD in the 7MM
• Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in the 7MM
• Treatment eligible pool for COPD in the 7MM

Download the report to understand which factors are driving the Chronic Obstructive Pulmonary Disease epidemiology trends.

Recent Developments In The COPD Treatment Landscape:

• In October 2025, GSK announced an agreement to acquire EMP-012, an experimental oligonucleotide therapy from Empirico designed to modulate gene expression and target an inflammatory pathway implicated in COPD. The drug has the potential to treat a broad spectrum of COPD patients and may be used as both monotherapy and in combination with other GSK therapies, offering significant opportunity in a market with insufficient treatment options.
• In September 2025, Sanofi announced that itepekimab is being explored in patients with COPD in two Phase 3 studies (AERIFY-1 and AERIFY-2) with readout anticipated in the second half of 2025. The company is also initiating a Phase 2/3 study in COPD with lunsekimig, expanding its biologic pipeline in this therapeutic area.
• In June 2025, The FDA approved Ohtuvayre (ensifentrine), a novel small-molecule dual G-protein coupled receptor agonist, as a maintenance treatment for COPD in adults. The approval was based on two Phase 3 clinical trials (ENHANCE-1 and ENHANCE-2) demonstrating superior improvement in lung function compared to placebo in patients with moderate-to-severe COPD.
• In May 2025, GSK received FDA approval for NUCALA (mepolizumab) for COPD, marking the first IL-5 inhibitor approved for this indication and expanding the biologic therapies landscape. NUCALA is validated in patients with elevated eosinophils (≥150 cells/μL), offering utility in patients with chronic bronchitis and persistent eosinophilia.
• In March 2025, DUPIXENT (dupilumab) received its Japanese approval as the first biologic COPD therapy in the country, significantly advancing biomarker-driven treatment approaches in the Asia-Pacific region and broadening access to precision medicine-based COPD management.

Chronic Obstructive Pulmonary Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the COPD market or expected to get launched during the study period. The analysis covers COPD market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the COPD Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Obstructive Pulmonary Disease Therapies and Key Companies

• DUPIXENT (dupilumab): Sanofi/Regeneron
• NUCALA (mepolizumab): GSK
• FASENRA (benralizumab): AstraZeneca
• Ohtuvayre (ensifentrine): Aytu BioPharma
• Trelegy Ellipta (fluticasone/umeclidinium/vilanterol): GSK
• Advair (fluticasone/salmeterol): GSK
• Ultibro Breezhaler (indacaterol/glycopyrronium): Novartis
• Anoro Ellipta (umeclidinium/vilanterol): GSK
• Incruse Ellipta (umeclidinium): GSK
• Seebri Breezhaler (glycopyrronium): Novartis
• EMP-012: GSK/Empirico
• Lunsekimig: Sanofi
• Itepekimab: Sanofi
• LAMA/LABA combinations: Multiple manufacturers

To know more about COPD companies working in the treatment market, visit Chronic Obstructive Pulmonary Disease Competitive Landscape

Chronic Obstructive Pulmonary Disease Market Drivers

• Increasing prevalence of COPD globally, driven by aging populations and continued exposure to risk factors including smoking and air pollution
• Growth of biologic therapies and targeted immunotherapies for biomarker-defined COPD subtypes, particularly eosinophil-high phenotypes
• Advancements in molecular diagnostics and eosinophil count-based patient stratification enabling precision medicine approaches
• Rising healthcare expenditure and government initiatives supporting respiratory disease management and screening programs
• Expanding awareness and early diagnosis through spirometry-based screening programs and public health campaigns
• Development of combination therapies and novel drug delivery systems improving patient outcomes and reducing exacerbation rates
• Growing market penetration in emerging regions with improving healthcare infrastructure and disease awareness

Chronic Obstructive Pulmonary Disease Market Barriers

• High cost of biologic therapies and advanced treatments limiting patient access in resource-limited settings
• Complex clinical trial designs and lengthy regulatory approval processes for novel COPD therapeutics
• Resistance and inadequate response to existing treatments reducing long-term efficacy in specific patient populations
• Limited awareness and accessibility in emerging markets and underdiagnosis of COPD
• Side effects and safety concerns associated with advanced biologic therapies
• Variability in patient response due to genetic, environmental, and phenotypic factors
• Generic competition and pricing pressures on traditional COPD medications, including triple-therapy inhalers

Scope of the Chronic Obstructive Pulmonary Disease Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key COPD Companies: GSK, AstraZeneca, Sanofi, Regeneron, Genentech/Roche, Takeda, Boehringer Ingelheim, Pfizer, Novartis, Mitsubishi Tanabe Pharma, Zambon, Chiesi, Sunovion, Mundipharma, Mylan, Teva, Sandoz, and others
• Key COPD Therapies: DUPIXENT (dupilumab), NUCALA (mepolizumab), FASENRA (benralizumab), Trelegy Ellipta, Advair, Ohtuvayre (ensifentrine), EMP-012, Lunsekimig, Itepekimab, and others
• COPD Therapeutic Assessment: COPD current marketed and COPD emerging therapies
• COPD Market Dynamics: COPD market drivers and COPD market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• COPD Unmet Needs, KOL's views, Analyst's views, COPD Market Access and Reimbursement

Discover More About Therapies Set to Grab Major COPD Market Share @ Chronic Obstructive Pulmonary Disease Treatment Market